thiazoles has been researched along with Aggressive Systemic Mastocytosis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (38.89) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calabrò, C; Gadaleta, CD; Laforgia, M; Marech, I; Nardulli, P; Ranieri, G | 1 |
| De Vita, S; Ebert, BL; Garcia, M; Gavillet, M; Gerbaulet, A; Levine, RL; Mullally, A; Roers, A; Schneider, RK; Williams, DA; Wood, J | 1 |
| Barra, FF; Costa, FF; de Melo Campos, P; Duarte, AS; Lorand-Metze, I; Machado-Neto, JA; Olalla Saad, ST; Rogers, HJ; Scopim-Ribeiro, R; Tabarroki, A; Tiu, RV; Traina, F; Vassalo, J; Visconte, V | 1 |
| Afrin, LB; Agopian, J; Auclair, C; Barete, S; Bulai Livideanu, C; Canioni, D; Chandesris, MO; Damaj, G; Dubreuil, P; Fraitag, S; Frenzel, L; Gaillard, R; Georgin Lavialle, S; Grattan, C; Guillet, G; Hanssens, K; Hermine, O; Jassem, E; Kinet, JP; Lhermitte, L; Lortholary, O; Mansfield, C; Moussy, A; Niedoszytko, M; Paul, C; Verstovsek, S | 1 |
| Akin, C; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Manshouri, T; O'Brien, S; Pardanani, A; Tefferi, A; Thomas, D; Verstovsek, S | 1 |
| Bhalla, K; Corless, CL; Fiskus, W; Heinrich, MC; Jillella, A; Kepten, I; Lewis, G; Manaloor, E; Ramalingam, P; Savage, N; Ustun, C | 1 |
| Aichberger, KJ; Gleixner, KV; Kretschmer, A; Sperr, WR; Valent, P | 1 |
| Baumgartner, C; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Peter, B; Pickl, WF; Rebuzzi, L; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Gleixner, KV; Hadzijusufovic, E; Mirkina, I; Peter, B; Pickl, WF; Schuch, K; Thaiwong, T; Valent, P; Willmann, M; Yuzbasiyan-Gurkan, V | 1 |
| Barete, S; Casassus, P; Dubreuil, P; Gineste, P; Grandpeix-Guyodo, C; Hermine, O; Lanternier, F; Lortholary, O; Mansfield, CD; Moussy, A; Palmérini, F; Paul, C; Sans, B; Suarez, F | 1 |
| Pardanani, A | 1 |
| Bueso-Ramos, C; Chen, SS; Cortes, JE; Esmaeli, B; Katz, RL; Khanna, A; Manning, JT; Miranda, RN; Shinder, R; Verstovsek, S; Vigil, CE; Wang, SA; You, MJ | 1 |
| Akin, C; DeRemer, DL; Ustun, C | 1 |
| Bennett, KL; Cerny-Reiterer, S; Gleixner, KV; Gotlib, J; Hadzijusufovic, E; Hörmann, G; Horny, HP; Mayerhofer, M; Meyer, RA; Mitterbauer-Hohendanner, G; Pickl, WF; Reiter, A; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Arock, M; Auclair, C; Bougherara, H; Damaj, G; Dubreuil, P; Georgin-Lavialle, S; Hermine, O; Launay, JM; Lhermitte, L; Poul, MA | 1 |
| Akin, C; Donker, M; Jiang, Y; Lee, FY; Luo, R; Shah, NP | 1 |
| Aichberger, KJ; Baumgartner, C; Fabbro, D; Gleixner, KV; Gruze, A; Lee, FY; Manley, PW; Mayerhofer, M; Pickl, WF; Samorapoompichit, P; Sillaber, C; Sonneck, K; Valent, P | 1 |
| Augustson, B; Cannell, P; Carnley, B; Cooney, J; Cull, G; Purtill, D; Sinniah, R | 1 |
2 review(s) available for thiazoles and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
An evaluation of masitinib for treating systemic mastocytosis.
Topics: Benzamides; Humans; Imatinib Mesylate; Mast Cells; Mastocytosis, Systemic; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Thiazoles | 2019 |
Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Topics: Animals; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2011 |
3 trial(s) available for thiazoles and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Asthenia; Benzamides; Diarrhea; Double-Blind Method; Exanthema; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Thiazoles; Treatment Outcome; Urticaria; Young Adult | 2017 |
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Philadelphia Chromosome; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2008 |
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Topics: Adult; Benzamides; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mastocytosis, Cutaneous; Mastocytosis, Systemic; Middle Aged; Mutation, Missense; Piperidines; Pyridines; Thiazoles; Treatment Outcome | 2010 |
13 other study(ies) available for thiazoles and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.
Topics: Animals; Azacitidine; Blotting, Western; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dasatinib; Decitabine; Dioxygenases; Disease Models, Animal; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Inhibitors; Esophagus; Gastric Mucosa; Humans; Mast Cells; Mastocytosis, Systemic; Mice, Knockout; Mice, Transgenic; Mutation, Missense; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; Skin; Stomach; Thiazoles | 2014 |
Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
Topics: Adult; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Dasatinib; Female; Germ-Line Mutation; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles; Young Adult | 2014 |
Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
Topics: Antineoplastic Agents; Blotting, Western; Dasatinib; DNA Primers; DNA Probes; Electrophoresis, Polyacrylamide Gel; Humans; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Pyrimidines; Remission Induction; Thiazoles | 2009 |
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.
Topics: Aged; Antineoplastic Agents; Cladribine; Dasatinib; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Leukemia, Mast-Cell; Mastocytosis, Systemic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Failure; Tryptases | 2008 |
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Topics: Animals; Apoptosis; Base Sequence; Benzamides; Cat Diseases; Cats; Cell Proliferation; Dasatinib; DNA Primers; Exons; Female; Humans; Imatinib Mesylate; In Vitro Techniques; Male; Mast Cells; Mastocytosis, Systemic; Molecular Sequence Data; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Tandem Repeat Sequences; Thiazoles | 2009 |
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.
Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cats; Cell Line, Tumor; Cell Proliferation; Dasatinib; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Histamine H1 Antagonists, Non-Sedating; Humans; Inhibitory Concentration 50; Loratadine; Mastocytoma; Mastocytosis, Systemic; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Terfenadine; Thiazoles; Tumor Cells, Cultured | 2010 |
Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Cladribine; Dasatinib; Disease-Free Survival; Humans; Hydroxyurea; Imatinib Mesylate; Interferon Type I; Mast Cells; Mastocytosis, Systemic; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Recombinant Proteins; Risk; Staurosporine; Thiazoles | 2011 |
Dasatinib-responsive mast cell neoplasms as initial presentation of chronic myelogenous leukemia in blast phase.
Topics: Blast Crisis; Bone Marrow; Dasatinib; Femur; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; Orbital Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles | 2011 |
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Topics: Agammaglobulinaemia Tyrosine Kinase; Aniline Compounds; Cell Line, Tumor; Dasatinib; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mast Cells; Mastocytosis, Systemic; Mutation; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolines; Signal Transduction; src-Family Kinases; Staurosporine; Thiazoles; Tumor Cells, Cultured | 2011 |
Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Membrane; Dasatinib; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Thiazoles; Young Adult | 2013 |
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Topics: Animals; Benzamides; Binding Sites; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Ligands; Mastocytosis, Systemic; Mice; Models, Molecular; Mutation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2006 |
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Survival; Dasatinib; Drug Synergism; Humans; Mast Cells; Mastocytosis, Systemic; Mutation, Missense; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Staurosporine; Thiazoles | 2007 |
Dasatinib therapy for systemic mastocytosis: four cases.
Topics: Adult; Dasatinib; Female; Humans; Male; Mastocytosis, Systemic; Middle Aged; Pyrimidines; Thiazoles | 2008 |